On the basis of present evidence, intracoronary BMC infusion in patients with AMI seems to be safe and associated with slight improvement of the left ventricular ejection fraction at 3-6 months' follow-up.

No abstract

ObjectivesThe study reports the final 5‐year safety and effectiveness outcomes of the novel abluminal groove‐filled biodegradable polymer‐coated FIREHAWK sirolimus‐eluting stent in a large patient cohort.BackgroundThe TARGET clinical program was conducted to evaluate the performance of the FIREHAWK stent, and this objective performance criterion study pooled long‐term safety and efficacy data from three TARGET trials for greater statistical power to analyze low‐frequency events.MethodsPatient‐level pooled data from 1,007 individuals in the TARGET I randomized controlled trial (n = 227), TARGET I long lesion cohort (n = 50), and TARGET II registry (n = 730) were prospectively collected and analyzed. The primary endpoint, target lesion failure (TLF), was defined as a composite of cardiac death, target vessel myocardial infarction (TV‐MI), and ischemia‐driven indicated target lesion revascularization (ID‐TLR) at 5 years. All patients were exclusively treated with the FIREHAWK stent and had annual follow‐up visits for up to 5 years.ResultsAmong 947 patients (94.0%) who completed the 5‐year clinical follow‐up, the 5‐year TLF event rate was 8.1%; the events included 18 cardiac deaths, 36 TV‐MIs, and 33 ID‐TLRs. Only four (0.4%) very late probable or definite stent thrombosis events were observed beyond 1 year after stent implantation. In the subgroup analysis, lesion length ≥ 30 mm was associated with higher long‐term TLF incidence, while the use of a predilation‐sizing‐postdilation technique showed no significant effect on long‐term outcomes.ConclusionsFive‐year results demonstrate the continuing safety and efficacy of the FIREHAWK Stent, with relatively lower incidence of thrombotic events.

Transplantation of either MNC or EPC may be beneficial to cardiac systolic function, but might not has obvious effect on diastolic function. Intracoronary infusion of EPC might be better than MNC in controlling infarction size. Both MNC and EPC may stimulate angiogenesis, inhibit fibrogenesis, and differentiate into myocardial cells.

No abstract

Background:It has long been a controversial hotspot whether resting heart rate (RHR) is a risk factor or a marker for death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, is a pure RHR lowering agent. The study was aimed to investigate whether ivabradine would reduce more RHR, cardiovascular disease (CVD) mortality, and all-cause mortality than those placebo or beta-blockers.Methods:The authors performed a meta-analysis of 8 randomized controlled clinical studies (with 40,357 participants), and 3 studies of those which were ivabradine versus placebo (36,069 participants) and other 5 studies ivabradine versus beta-blockers (4288 participants) were available. The authors compared the association of the RHR reduction with death from CVD causes (2674 in 40,285 participants) and the rate of all-cause death (3143 deaths in 38,037 participants), and assessed improvement in death rates with the use of ivabradine.Results:The change of RHR from baseline to endpoint was 8 to 16 beats/min (bpm) in ivabradine group, 1 to 8 bpm in placebo group, and 4 to 24 bpm in beta-blockers group. In ivabradine versus placebo, the reduced risks of CVD mortality and all-cause morbidity were not significantly (risk ratio [RR] 1.02; 95% confidence interval [CI] 0.91–1.14, P = .737; RR: 1.00, 95% CI: 0.92–1.09, P = .992, respectively). CVD and all-cause morbidity were similar for ivabradine versus beta-blockers (RR: 1.04; 95% CI: 0.80–1.37, P = .752; RR: 1.17, 95% CI: 0.53–2.60, P = .697, respectively).Conclusions:Ivabradine had a neutral effect on mortality, suggesting that a pure RHR lowering agent did not reduce CVD mortality, all-cause mortality and improve the lifespan.

This paper analyzes the characteristics of a large power surface magnet PMSM with sinusoidal windings used in a marine propulsion system using phasor diagrams. Also, these characteristics are simulated using MATLAB. The analysis and simulation are done for three different types of current control schemes, that is, the isd -0 control method, unity power factor control method, and constant air-gap flux linkage control method. Based on the performance of the PMSM under these different control methods, a conclusion is drawn that the isd -0 control method is superior to the other two control methods in marine propulsion systems when the armature reaction reactance is low. I. INTRODUCTIONElectrically driven propulsion systems offer the prospect of improved maneuverability, greater efficiency, reduced acoustic noise and greater flexibility of equipment layout. So they are widely used in both surface and submersible marine crafts.Over the last decade, a new propulsion named "podded propulsion" is becoming increasingly popular as an alternative to "conventional" diesel-mechanical or dieselelectrical propulsion especially in cruise ships. Podded propulsion is an electric drive propulsion unit, azimuthing through 360 degrees around its vertical axis. The azimuthing unit incorporates an electric AC motor, which directly drives a fixed pitch propeller. The electric motor is speed controlled by a frequency converter, with full torque available in either direction from zero to nominal speed. The main important features for podded propulsion are less noise, improved maneuverability, additional space for extra payload, energy saving and more speed. Due to the above-mentioned key benefits along with some other associated advantages, pods are receiving increased attention for other types of ships like tankers, ice going vessels, supply vessels and semi-submersibles.Marine propulsion system needs large power motor. The large power electric AC motor is placed in the waterproof pod for podded propulsion. So problems caused by the volume, weight, ventilation, etc. of the motor arise.Using new magnet materials for field excitation, the PMSM allows a considerable reduction in motor volume, weight and inertia with attendant increases in specific power and torque. Another advantage of the PMSM is that the PMSM doesn't need cooling systems for the rotor due to no heat generated from it. These advantages, coupled with the development of power electronics and control techniques, make the large power PMSM popular in the application of marine propulsion systems.

Transplantation of BM-MNC into myocardium with ischemic reperfusion injury increases capillary density and decreases infarction area. It has significantly beneficial effect on cardiac systolic function rather than on diastolic function.